Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Lifevantage Corporation (LFVN : NSDQ)

• Company Description    Lifevantage Corporation is a health and nutrition company. The company is the maker of Protandim(R), the Nrf2 Synergizer(R) patented dietary supplement, the TrueScience(TM) Anti-Aging Skin Care Regimen, Canine Health and the AXIO(TM) energy product line. Lifevantage Corporation is headquartered in Salt Lake City, Utah. Number of Employees: 238

• Price / Volume Information    Yesterday's Closing Price: $11.13 Daily Weekly Monthly 20 Day Moving Average: 145,177 shares Shares Outstanding: 12.69 (millions) Market Capitalization: $141.25 (millions) Beta: 0.39 52 Week High: $27.38 52 Week Low: $9.77 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -18.64% -20.07% 12 Week -11.88% -19.95% Year To Date -36.51% -40.31%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3300 N. TRIUMPH BLVD SUITE 700 - LEHI,UT 84043 USA ph: 801-432-9000 fax: 801-880-0699 reed.anderson@icrinc.com http://www.lifevantage.com

• General Corporate Information    Officers Steven R. Fife - Chief Executive Officer; President Raymond B. Greer - Chairman Rajendran Anbalagan - Director Michael A. Beindorff - Director Dayton Judd - Director Peer Information Lifevantage Corporation (ITRJ) Lifevantage Corporation (BRLI.) Lifevantage Corporation (GOGY) Lifevantage Corporation (PSTX.) Lifevantage Corporation (ELGXQ) Lifevantage Corporation (CAH) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED/DENTAL-SUPP Sector: Medical CUSIP: 53222K205 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/04/25 Share - Related Items Shares Outstanding: 12.69 Most Recent Split Date: 10.00 (0.14:1) Beta: 0.39 Market Capitalization: $141.25 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 1.62% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.18 Current Fiscal Year EPS Consensus Estimate: $1.05 Payout Ratio: 0.22 Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: -0.08 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/25

• Fundamental Ratios P/E Current FY Estimate: 10.60 Trailing 12 Months: 13.91 PEG Ratio: - Price Ratios Price/Book: 4.04 Price/Cash Flow: 10.13 Price / Sales: 0.62 EPS Growth vs. Year Ago Period: 21.43% vs. Previous Quarter: -34.62% Sales Growth vs. Year Ago Period: 12.64% vs. Previous Quarter: -5.69% ROE 06/30/25 - 33.75 03/31/25 - 34.67 12/31/24 - 34.29 ROA 06/30/25 - 15.26 03/31/25 - 15.24 12/31/24 - 15.04 Current Ratio 06/30/25 - 1.87 03/31/25 - 1.66 12/31/24 - 1.66 Quick Ratio 06/30/25 - 1.11 03/31/25 - 0.98 12/31/24 - 1.03 Operating Margin 06/30/25 - 4.66 03/31/25 - 4.58 12/31/24 - 4.46 Net Margin 06/30/25 - 4.29 03/31/25 - 4.12 12/31/24 - 3.46 Pre-Tax Margin 06/30/25 - 5.36 03/31/25 - 5.65 12/31/24 - 4.86 Book Value 06/30/25 - 2.75 03/31/25 - 2.71 12/31/24 - 2.39 Inventory Turnover 06/30/25 - 2.32 03/31/25 - 2.45 12/31/24 - 2.66 Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©